The 2017 ACC Expert Consensus Decision Pathway provides a standardized framework for the periprocedural interruption, bridging, and restarting of anticoagulation in nonvalvular atrial fibrillation.
How should clinicians manage periprocedural anticoagulation (interruption, bridging, and restarting) in patients with nonvalvular atrial fibrillation?
This ACC expert consensus provides a standardized decision pathway for the complex periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation.
Periprocedural management of anticoagulation is a common clinical conundrum that involves a multidisciplinary team, cuts across many specialties, and varies greatly between institutions in the way it is practiced. Nowhere is this more evident than in the management of patients with nonvalvular atrial fibrillation. Although they have been found to improve patient outcomes, standardized evidence-based protocols are infrequently in place. The frequency of anticoagulant interruption in preparation for a procedure is high, with an estimated 250,000 patients undergoing temporary interruption annually in North America alone. Knowledge about risk of bleeding and short-term thrombotic risk resides in many specialties, further complicating the issue. Our goal in creating this pathway is to help guide clinicians in the complex decision making in this area. In this document, we aim to: 1) validate the appropriateness of the decision to chronically anticoagulate; 2) guide clinicians in the decision of whether to interrupt anticoagulation; 3) provide direction on how to interrupt anticoagulation with specific guidance for vitamin K antagonists and direct-acting oral anticoagulants; 4) evaluate whether to bridge with a parenteral agent periprocedurally; 5) offer advice on how to bridge; and 6) outline the process of restarting anticoagulation post-procedure.
“This pathway makes decision making easier, especially regarding whether anticoagulation needs to be interrupted and whether the patient needs to be bridged. The result is that patients with very low bleeding risk procedures and no patient-related bleeding risks can often be managed without interruption. By following the guidance of this pathway, the primary care physician will be in a position to make evidence-based recommendations to the care team. By reserving bridging to high thrombotic risk patients, fewer patients will need to be bridged with a parenteral agent.”
Doherty et al. (Mon,) conducted a review in Nonvalvular Atrial Fibrillation. Periprocedural management of anticoagulation was evaluated. The 2017 ACC Expert Consensus Decision Pathway provides a standardized framework for the periprocedural interruption, bridging, and restarting of anticoagulation in nonvalvular atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: